NEW YORK (GenomeWeb) – Sygnis said today that it has signed a distribution agreement with Cambridge Bioscience for the commercialization of Sygnis' product portfolio in the UK and Ireland.
Under the agreement, Cambridge Bioscience will promote, market, sell, and support Sygnis' TruePrime products for primer-free whole-genome amplification, as well as its SunScript thermostable reverse transcriptase kits to molecular biologists.
TruePrime is based on Sygnis' multiple displacement amplification technology, while its SunScript product uses a proprietary engineered reverse transcriptase that Sygnis said is one of the most thermostable and fastest enzymes on the market.
Cambridge Bioscience is a UK-based distributor of research products for molecular biology applications such as NGS, epigenetics, gene regulation, and cloning; DNA extraction, purification, amplification, quantification, and delivery; and instrumentation.